0001193125-22-296502.txt : 20221201 0001193125-22-296502.hdr.sgml : 20221201 20221201160155 ACCESSION NUMBER: 0001193125-22-296502 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221201 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221201 DATE AS OF CHANGE: 20221201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 221438823 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-409-5300 MAIL ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140813 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 8-K 1 d418095d8k.htm 8-K 8-K
NASDAQ false 0001445283 0001445283 2022-12-01 2022-12-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 1, 2022

 

 

YUMANITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37695   20-8436652

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

40 Guest Street, Suite 4410

Boston, MA

   02135
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: 617-409-5300

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   YMTX   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01.

Regulation FD Disclosure.

As previously disclosed, on June 5, 2022, Yumanity Therapeutics, Inc., a Delaware corporation (“Yumanity”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceutica NV (“Janssen”). Concurrently with the execution of the Asset Purchase Agreement, on June 5, 2022, Yumanity entered into an Agreement and Plan of Merger with Kineta, Inc., a Washington corporation (“Kineta”), and Yacht Merger Sub, Inc., a Washington corporation and wholly-owned subsidiary of Yumanity.

On December 1, 2022, Kineta issued a press release announcing that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022. Dr. Guillaudeux will give an oral presentation on KVA12123 (formerly referred to as KVA12.1), Kineta’s VISTA blocking immunotherapy. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Important Information and Where to Find It

This communication may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen. In connection with the proposed transactions, on August 29, 2022, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Initial Registration Statement”), as amended by Amendment No. 1 to the Initial Registration Statement filed with the SEC on October 3, 2022, Amendment No. 2 to the Initial Registration Statement filed with the SEC on October 24, 2022 and Amendment No. 3 to the Initial Registration Statement filed with the SEC on November 4, 2022 (together with the Initial Registration Statement, the “Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has been declared effective by the SEC on November 10, 2022. Yumanity subsequently filed the definitive proxy statement/prospectus (the “Proxy Statement”) on November 10, 2022, which has been mailed to stockholders of record as of the close of business on November 4, 2022. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they contain important information about Yumanity, Kineta and the proposed transactions. This communication is not a substitute for the Registration Statement, the Proxy Statement or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions. Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Participants in the Solicitation

Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the Proxy Statement and will be set forth in any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibit furnished herewith contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; the listing of the combined company on Nasdaq after the closing of the proposed merger; expectations regarding the ownership structure of the combined company after the closing of the proposed merger; the expected executive officers and directors of the combined company; the expected cash position of each of Yumanity and Kineta and the combined company at the closing of the proposed merger; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; the executive and board structure of the combined company; the location of the combined company’s corporate headquarters; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; Kineta having sufficient resources to advance its pipeline; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the risk that the conditions to the closing of the proposed transactions are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Yumanity, Kineta and Janssen to consummate the proposed merger or asset sale, as applicable; (iii) risks related to Yumanity’s ability to manage its operating expenses and its expenses associated with the proposed transactions pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) the risk that as a result of adjustments to the exchange ratio, Yumanity stockholders and Kineta shareholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Yumanity’s common stock relative to the exchange ratio; (vii) unexpected costs, charges or expenses resulting from either or both of the proposed transactions; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transactions; (ix) the risk that the amount of the dividend distributed to Yumanity stockholders in connection with the asset sale, if any, may be lower than currently anticipated; (x) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xiii) risks associated with the possible failure to realize certain anticipated benefits of the proposed transactions, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Yumanity’s most recent Annual or Quarterly Report filed with the SEC, and in other filings that Yumanity makes and will make with the SEC in connection with the proposed transactions, including the Proxy Statement. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Except as required by law, Yumanity expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press release, dated December 1, 2022.
 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Yumanity Therapeutics, Inc.
Date: December 1, 2022     By:  

/s/ Richard Peters

      Richard Peters
      President and Chief Executive Officer
 EX-99.1 2 d418095dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

Seattle, WA — (December 1, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022. Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will give an oral presentation on KVA12123 (formerly referred to as KVA12.1). KVA12123 is the Company’s VISTA blocking immunotherapy that is expected to initiate Phase 1 clinical trials in patients with advanced solid tumors in the fourth quarter of 2022.

Presentation Details:

 

Title:   KVA12123 (formerly referred to as KVA12.1), a VISTA Blocking Immunotherapy
Presenter:   Thierry Guillaudeux, Ph.D.
Date / Time:   December 7, 2022, at 8:45 A.M. Pacific Time
Session Type:   Oral Presentation

A copy of the presentation will be available on the Kineta website under Publications after the conference on December 7, 2022: https://kinetabio.com/vista/#publications

####

Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

PiiONEER™ Platform is aimed at developing fully human antibodies to address the major mechanisms of cancer immune resistance including immuno-suppression, exhausted T cells and poor tumor immunogenicity. Utilization of the PiiONEER™ Platform is designed to result in novel, well-characterized innate immuno-oncology lead antibody therapeutics that can be efficiently advanced into formal investigational new drug (IND)-enabling and clinical studies.

LOGO

 

KVA12123 (formerly referred to as KVA12.1) is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12123.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta and between Yumanity and Janssen Pharmaceutica NV (“Janssen”). In connection with the proposed transactions, on August 29, 2022, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Initial Registration Statement”), as amended by Amendment No. 1 to the Initial Registration Statement filed with the SEC on October 3, 2022, Amendment No. 2 to the Initial Registration Statement filed with the SEC on October 24, 2022 and Amendment No. 3 to the Initial Registration Statement filed with the SEC on November 4, 2022 (together with the Initial Registration Statement, the “Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has been declared effective by the SEC on November 10, 2022. Yumanity subsequently filed the definitive proxy statement/prospectus (the “Proxy Statement”) on November 10, 2022, which is being mailed to Yumanity stockholders of record as of the close of business on November 4, 2022. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, the Proxy Statement or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the Proxy Statement and will be set forth in any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

LOGO

 

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kineta, Inc. :

Jacques Bouchy

EVP Investor Relations & Business Development

+1 206-378-0400

jbouchy@kineta.us

Investor Relations:

John Mullaly

LifeSci Advisors, LLC

jmullaly@lifesciadvisors.com

Source: Kineta, Inc.

EX-101.SCH 3 ymtx-20221201.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ymtx-20221201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ymtx-20221201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g418095dsp1.jpg GRAPHIC begin 644 g418095dsp1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Dec. 01, 2022
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001445283
Document Type 8-K
Document Period End Date Dec. 01, 2022
Entity Registrant Name YUMANITY THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37695
Entity Tax Identification Number 20-8436652
Entity Address, Address Line One 40 Guest Street
Entity Address, Address Line Two Suite 4410
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02135
City Area Code 617
Local Phone Number 409-5300
Written Communications true
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol YMTX
Entity Emerging Growth Company false
XML 8 d418095d8k_htm.xml IDEA: XBRL DOCUMENT 0001445283 2022-12-01 2022-12-01 NASDAQ false 0001445283 8-K 2022-12-01 YUMANITY THERAPEUTICS, INC. DE 001-37695 20-8436652 40 Guest Street Suite 4410 Boston MA 02135 617 409-5300 true false false false Common Stock, par value $0.001 per share YMTX false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d418095d8k.htm 7 d418095d8k.htm d418095dex991.htm ymtx-20221201.xsd ymtx-20221201_lab.xml ymtx-20221201_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d418095d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d418095d8k.htm" ] }, "labelLink": { "local": [ "ymtx-20221201_lab.xml" ] }, "presentationLink": { "local": [ "ymtx-20221201_pre.xml" ] }, "schema": { "local": [ "ymtx-20221201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ymtx", "nsuri": "http://yumanity.com/20221201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d418095d8k.htm", "contextRef": "duration_2022-12-01_to_2022-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d418095d8k.htm", "contextRef": "duration_2022-12-01_to_2022-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://yumanity.com//20221201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-296502-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-296502-xbrl.zip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end